Thus, our study reveals a YAP–P-body positive regulatory axis in CRC, which exposes the vital role of YAP/TAZ in the biogenesis of P-bodies in tumors and implies that reexpression of PNRC1 or disruption of P-bodies is a potential therapeutic strategy for cancers with active YAP. Here, PNRC1 is linked to cancer.